- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT06323174
Egy kutatási tanulmány annak megállapítására, hogy a CagriSema mennyivel csökkenti a vércukorszintet és a testsúlyt a placebóhoz képest olyan 2-es típusú cukorbetegeknél, akiket diétával és testmozgással kezelnek (REIMAGINE 1)
Az együtt adott Cagrilintide és Szemaglutid (CagriSema) s.c. hatékonysága és biztonságossága. heti egyszeri 2,4 mg/2,4 mg és 1,0 mg/1,0 mg dózisban, szemben a placebóval azoknál a résztvevőknél, akiknél a 2-es típusú cukorbetegség nem megfelelően kontrollált étrenddel és testmozgással
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 3. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
California
-
Huntington Park, California, Egyesült Államok, 90255
- Nat Res Inst Huntington Park
-
Northridge, California, Egyesült Államok, 91325
- Valley Clinical Trials, Inc.
-
Santa Ana, California, Egyesült Államok, 92701
- Southern California Dermatology
-
-
Florida
-
Hollywood, Florida, Egyesült Államok, 33024
- Encore Medical Research LLC
-
Orlando, Florida, Egyesült Államok, 32819
- Headlands Research Orlando
-
Weston, Florida, Egyesült Államok, 33331
- Encore Medical Research of Weston
-
-
Kansas
-
Newton, Kansas, Egyesült Államok, 67114
- Alliance for Multispec Res
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Troy, Michigan, Egyesült Államok, 48098
- Arcturus HC PLC Troy Med Res
-
-
New York
-
West Seneca, New York, Egyesült Államok, 14224
- Southgate Medical Group, LLP
-
-
Oregon
-
Portland, Oregon, Egyesült Államok, 97210
- Summit Research Network Oregon Inc.
-
-
Tennessee
-
Kingsport, Tennessee, Egyesült Államok, 37660
- Holston Medical Group
-
-
Texas
-
Amarillo, Texas, Egyesült Államok, 79124
- Amarillo Medical Specialists
-
Austin, Texas, Egyesült Államok, 78704
- Elligo Clin Res Centre
-
Brownsville, Texas, Egyesült Államok, 78526
- Headlands Research Brownsville
-
Dallas, Texas, Egyesült Államok, 75230
- Velocity Clinical Res-Dallas
-
San Antonio, Texas, Egyesült Államok, 78233
- Northeast Clinical Research of San Antonio
-
Shavano Park, Texas, Egyesült Államok, 78231
- Consano Clinical Research, LLC
-
Sugar Land, Texas, Egyesült Államok, 77479
- Sugar Lakes Family Practice PA
-
Weslaco, Texas, Egyesült Államok, 78596
- Valley Diab. & Endo Comp Ctr
-
-
Virginia
-
Newport News, Virginia, Egyesült Államok, 23606
- TPMG Clinical Research
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kína, 100853
- Chinese People's Liberation Army General Hospital-Endocrinology
-
-
Jiangsu
-
Nanjing, Jiangsu, Kína, 210011
- The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
-
Zhenjiang, Jiangsu, Kína, 212001
- The Affiliated Hospital of Jiangsu University-Endocrinology
-
-
Shandong
-
Ji'Nan, Shandong, Kína, 250000
- Jinan Central Hospital
-
Jinan, Shandong, Kína, 250000
- Jinan Central Hospital
-
-
-
-
-
Bialystok, Lengyelország, 15-351
- Osteo-Medic s.c. A. Racewicz, J. Supronik
-
Bialystok, Lengyelország, 15-797
- Renew Clinic Sp. z o.o.
-
Lodz, Lengyelország, 90-338
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
-
Warsaw, Lengyelország, 02-507
- Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
-
Warsaw, Lengyelország, 00-710
- NBR Polska Tomasz Klodawski
-
Zamość, Lengyelország, 22-400
- Velocity Nova Sp. z o.o.
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Lengyelország, 35-055
- Centrum Medyczne Medyk Sp. z o.o.
-
-
-
-
-
Budapest, Magyarország, 1032
- Szent Margit Rendelőintézet Nonprofit Kft.
-
Budapest, Magyarország, 1102
- PVN Kutató Kft.
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Magyarország, 4025
- Belinus Bt.
-
-
Szabolcs-Szatmar Varmegye
-
Nyíregyháza, Szabolcs-Szatmar Varmegye, Magyarország, 4405
- Borbánya Praxis E.Ü. Kft.
-
-
-
-
-
Bergamo, Olaszország, 24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Catanzaro, Olaszország, 88100
- Policlinico Mater Domini Università di Catanzaro
-
Milan, Olaszország, 20132
- IRCCS Ospedale San Raffaele Milano
-
Roma, Olaszország, 00161
- Azienda Ospealiero Universitaria Policlinico Umberto I
-
-
-
-
-
Al Ahsa, Szaud-Arábia, 36428
- King Abdulaziz Hospital-Al Ahsa-National Guard
-
Jeddah, Szaud-Arábia, 21423
- National Guard Hospital - Jeddah
-
Riyadh, Szaud-Arábia, 11525
- King Fahad Medical City
-
Riyadh, Szaud-Arábia, 12372
- King Khaled University Hospital,King Saud Univ. Med. City
-
Riyadh, Szaud-Arábia, 12769
- King Salman Bin Abdulaziz Hospital
-
-
-
-
-
Belgrade, Szerbia, 11080
- Clinical Hospital Center Bezanijska Kosa
-
Belgrade, Szerbia, 11080
- Clinical Hospital Centre Zemun
-
Belgrade, Szerbia, 11000
- CHC Zvezdara, Clinical department for endocrinology
-
Zaječar, Szerbia, 19000
- Policlinic for diabetes
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Male or female
- Age 18 years or above at the time of signing the informed consent
- Diagnosed with type 2 diabetes >=30 days before screening
- HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
- Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening
Exclusion Criteria:
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
- Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
- Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Négyszeres
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Aktív összehasonlító: CagriSema Dose 2
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Placebo Comparator: Placebo Dose 2
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
|
Aktív összehasonlító: Cagrisema Dose 1
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Placebo Comparator: Placebo Dose 1
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Change in glycated haemoglobin (HbA1c)
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as percentage (%)-points. |
From baseline (week 0) to end of treatment (week 40)
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Relative change in body weight
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured in %. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=15% body weight reduction
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Időkeret: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
Időkeret: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Change in Fasting Plasma Glucose (FPG)
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimoles per liter (mmol/L). |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=5% body weight reduction
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=20% body weight reduction
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in waist circumference
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured in centimeters (cm). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in systolic blood pressure (SBP)
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimeters of mercury (mmHg). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in diastolic blood pressure (DBP)
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured in mmHg. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Total cholesterol
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Triglycerides
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Free fatty acids
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Non-HDL cholesterol
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
Időkeret: At end of study (week 52)
|
Measured as count of participants. |
At end of study (week 52)
|
|
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Physical Component Summary score
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Mental Component Summary score
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in leptin
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured in nanograms per milliliter (ng/mL). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in soluble leptin receptor
Időkeret: From baseline (week 0) to end of treatment (week 40)
|
Measured in ng/mL. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of Treatment Emergent Adverse Events (TEAEs)
Időkeret: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of events. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
Időkeret: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Időkeret: From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Tanulmányi igazgató: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- NN9388-4895
- 2022-502677-42 (Egyéb azonosító: European Medical Agency (EMA))
- U1111-1283-0404 (Egyéb azonosító: World Health Organization (WHO))
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .